Female adults of many mosquito species possess distinct physiological features adapting to blood feeding for successful reproduction. The disease pathogens that are transmitted by mosquitoes have evolved to take advantages of the indispensable blood feedings to complete their transmission cycles and to survive attacks from the mosquito's innate immune system. Normal egg development and mosquito immunity are tightly controlled by tissue- and stage-specific gene expression and coordinated by many signal molecules in the mosquito. Understanding gene regulation affecting mosquito reproduction and malaria parasites infection is of paramount importance for developing novel malaria control strategies. A growing body of evidence indicates that microRNAs (miRNAs) are involved in egg maturation and immune reactions against invading pathogens in mosquitoes. However, the molecular mechanisms by which specific miRNAs selectively modulate reproduction and the survival of pathogens are largely unknown. The miRNA-induced gene-silencing pathway in mosquitoes was mostly extrapolated from the studies of flies. To explore the dynamics of miRNAs in reproduction, I used small RNAs sequencing to monitor miRNAs expression and their association with Argonaute 1 (Ago1) and Argonaute 2 (Ago2) in the malaria mosquito Anopheles gambiae (An. gambiae) during the 72-h period immediately after blood feeding. I found the abundance and Ago loading of most of the mature miRNAs were relatively stable after blood ingestion. However, miRNAs of the miR-309/286/2944 cluster were considerably upregulated after blood feeding. I confirmed that miR-309 is essential for normal egg development by depletion of endogenous miR-309 with a specific antagomir. In addition, my results showed that the Ago association of some miRNAs was not proportional to their cellular abundance implying additional regulation at miRNA integration. To investigate the functional roles of miRNAs and define context-dependent miRNA-mRNA interactions during the reproductive process, I have applied an innovative experimental approach to study miRNA-mRNA interactome. CLEAR (covalent ligation of endogenous Argonaute-bound RNAs)-CLIP can generate miRNA-mRNA chimeras from UV-irradiation stabilized Ago-miRNA-mRNA complex. My results have defined tens of thousands of miRNA-mRNA interactions in mosquitoes, including novel targets for mosquito-specific miRNAs. Verification of the predicted interactions using mRNA-seq, ribosome-profiling, and luciferase reporter assay revealed a reliable miRNA-mRNA interaction network. Based on the detected interactions, I refined the paring rules for mosquito miRNAs and illustrated the dynamic pairing between different regions of miRNAs with their targets in vivo. The miRNA-mRNA interactions were compared using this approach at multiple time points before and after blood feeding. Importantly, this study showed that the interactions were dynamic and enriched in genes that are involved in metabolisms, supporting the proposed functions of miRNAs in coordinating the gene regulation in mosquito reproduction. Plasmodium falciparum (P. falciparum) is a major human malaria parasite. To understand the functions of miRNAs in the mosquito resistance to Plasmodium infection, we analyzed the miRNA-mRNA interactions after female mosquitoes taking a P. falciparum-infected blood meal or an uninfected blood meal. Comparison of the interactions revealed enhanced miRNA-mRNA interactions after P. falciparum infection involving a group of immunity-related genes. In summary, this study has provided a systematic view and significantly advanced our understanding of the miRNA functions in mosquito reproduction and P. falciparum infection. / PHD / Female mosquito is able to transmit lots of disease to the human when it bites for blood. The blood meal provides necessary nutrient for mosquito reproduction and spread the pathogens such as malaria and Zika at the same time. Thus understanding the molecular mechanism behind this process would be greatly helpful to develop novel vector control strategy. Here, we found a distinct class of RNAs contributing to the regulation of mosquito blood meal and parasite infection. We used a novel biochemical method to decoding the special role of these kinds of RNAs in these processes. We found them regulating mosquito metabolism and immunity. This study significantly deepened our knowledge about the process of mosquito reproduction and transmitting diseases.

Huntingtons sjukdom (HD) är ett neurodegenerativt tillstånd som orsakas av mutationer i huntingtin gen (Htt), och resulterar till upprepade glutamin (polyQ) i Htt-proteinet. Muterad Htt kan inte vika sig ordentligt och börjar därför aggregera i celler. I detta projekt undersöktes molekylära mekanismerna bakom HD genom att analysera genuttryck hos musvävnader och jämföra detta med biomarkörer identifierats hos HD-patienter. För närvarande finns det ingen behandling för att stoppa utveckling av HD. Därför behövs det mer kunskap om sjukdomen. Projektets mål var att öka vår förståelse på regulatoriska mekanismer som ligger bakom den neurodegenerativa sjukdomen och identifiera potentiella diagnostiska biomarkörer. För denna studie användes mRNA-seq-data från 11 distinkta vävnader från Q175 HD-möss. Vävnader som analyserades inkluderar hjärnstammen, cerebellum, corpus callosum, hippocampus och thalamus/hypothalamus, fettvävnader (brun, vit nära gonad och vit nära tarm) och andra vävnader så som hjärta, hud och gastrocnemius muskel. Efter en grundlig genomgång av HD-litteraturen valdes biomarkörer som sedan undersöktes för mRNA-uttryck hos Q175-möss via Gene Set Enrichment Analysis (GSEA). Genuttrycksförändringar hos HD-möss visade sig vara vävnadsspecifika, med betydande effekter på hud och fettvävnader, men mindre effekter hos hjärnvävnader. Även om gemensamma mRNA-förändringar inte hittas bland de olika vävnader, uppvisade relaterade vävnader förändringar i samma pathways. Immunsvar och ribosomal dysfunktion var utbredd, men varje hjärnregion visade unika förändringar relaterade till sömn, synaptisk signalering och energiprocesser. Muskel- och fettvävnader uppvisar också distinkta mönstrar. Detta understryker vikten av vävnadsspecifik biomarkörforskning för neurodegenerativa sjukdomar. / Huntington's disease (HD) is a neurodegenerative condition caused by a mutation in the Huntingtin (Htt) gene which results in glutamine repeats (polyQ) and a longer Htt-protein. The mutated Htt-protein cannot fold properly and thus, is prone to aggregate in cells. There is currently no treatment available to stop the progression of HD. Therefore, there is a need for more knowledge regarding the disease. This project investigates the molecular mechanisms underlying HD by analysing gene expression program in wild type (Wt) and HD mice. The objective is to investigate changes in gene regulatory mechanisms underlying the neurodegenerative disease and identify potential diagnostic markers. For this study, mRNA-seq data from 11 distinct tissues from Q175 HD model mouse were analysed. These tissues included brainstem, cerebellum, corpus callosum, hippocampus, and thalamus/hypothalamus, adipose tissues (brown, white near gonad and white near intestine), heart, skin and gastrocnemius muscle. Following a thorough literature review, biomarkers of HD were chosen, and their expression investigated in the HD mouse using Gene Set Enrichment Analysis (GSEA). Gene expression changes in HD mouse were specific to different tissues, with significant changes identified in skin and adipose tissues, while smaller changes were detected in the brain tissues. While common changes across the 11 tissues were not found, related tissues exhibited alterations in the same pathways. Changes in immune response and ribosomal dysfunction were widespread across tissues. Moreover, each brain region showed unique changes related to sleep, synaptic signalling, and energy processes. Muscle and adipose tissues displayed distinctive patterns. These results underscore the importance of tissue-specific biomarker research for neurodegenerative diseases.

Kronisk myeloisk leukemi-celler kan överleva drogbehandling och utveckla resistens till dagens behandlingar som består av tyrosinkinasinhibitorer. Denna studie utforskar sättet på vilket K562 celler svarar till två tyrosinkinasinhibitorer, Imatinib och Bosutinib, på en transkriptionell nivå. Genom att designa studien kring ett tidsförlopp då prov för mRNA sekvensering togs vid en kontrolltidpunkt, 1, 6 och 24 timmar av behandling, samt en vecka efter 24 timmars behandling, med respektive läkemedel. K562 cellernas tillväxt var starkt hämmad av Bosutinib, även efter en veckas återhämtning från behandlingen. Imatinib-behandlade celler kunde växa nästan oförändrat både under och efter behandling. Skillnaden i inhibition av tillväxt mellan drogerna verkar även vara oberoende av dos, baserat på två testa koncentrationer för varje läkemedel: 1 µM och 3,9 µM för Imatinib, 1 µM och 0,27 µM av Bosutinib. Cellmorfologi var också ändrad av Bosutinib, då den var oförändrad vid behandling med Imatinib. Transkriptomiska analyser utfördes och gene set enrichment analysis (GSEA) användes tillsammans med over-representation analysis (ORA) för att identifiera mönster i genuttryck. Grupper av gener kopplade till nukleinsyrametabolism, RNA bearbetning och i synnerhet cellaktivering och proliferering var nedreglerade under behandling med båda läkemedlen. Efter återhämtning från behandling med Imatinib, K562 celler kunde återgå till deras ursprungliga transkriptionella profil, medan Bosutinib-behandlade celler upprätthöll långsiktig transkriptionell omprogrammering. MYC transkriptionsfaktorn var nedreglerad av både Imatinib och Bosutinib under behandlingen, och MYC kunde förknippas med en grupp av gener som var nedreglerade under läkemedelsbehandling. Resultaten i denna studie tydliggör att transkriptionell omprogrammering sker i K562 celler under behandling med TKI, och att denna omprogrammering sker på ett koordinerat sätt i grupper av gener relaterade till signaleringsvägar och viktiga cellulära processer. Hållbara förändringar i genuttryck efter Bosutinib-behandling kan länkas samman med drogens effektiva inhibition av cellernas tillväxt. / Chronic myeloid leukaemia cells are able to survive and develop resistance to current treatments consisting of tyrosine kinase inhibitors (TKIs). This study investigates the way in which K562 cells respond to two TKIs, Imatinib and Bosutinib, on a transcriptional level. Using a time course study design, mRNA sequencing (mRNA-seq) was performed on control, 1h, 6h and 24h treatment time points for each drug, as well as after one week of recovery following 24h of treatment. K562 proliferation was vastly inhibited by Bosutinib, even after one week of recovery from the 24-hour treatment period, while Imatinib-treated cells were able to proliferate almost normally during and after treatment. The difference in inhibitory effect between the two drugs seems to be dose-independent based on two tested concentrations, 1 µM and 3,9 µM Imatinib, as well as 1 µM and 0,27 µM Bosutinib. Cell morphology was also altered by Bosutinib while being unchanged during and after Imatinib treatment. Transcriptomics analysis was performed, and gene set enrichment analysis (GSEA) was used together with overrepresentation analysis (ORA) to identify patterns in gene expression. Groups of genes related to nucleic acid metabolism, RNA processing and notably regulation of cell activation and proliferation are repressed during both Imatinib and Bosutinib treatment. After recovery from Imatinib treatment, K562 cells are able to revert the transcriptional changes, while Bosutinib-treated cells sustain long-term transcriptional reprogramming. The MYC transcription factor is down-regulated by both drugs during treatment, and MYC is also linked to a collection of genes that are down-regulated during Imatinib and Bosutinib treatment. The findings from this study elucidate that transcriptional reprogramming occurs in K562 cells during TKI treatment, and that this reprogramming occurs in a concerted fashion across groups of genes related to signalling pathways and important cellular processes. Sustained changes in gene expression after Bosutinib treatment can linked to the drug’s effectiveness at inhibiting K562 cell growth.

Syftet med detta projekt var att undersöka hur vanligt använda cancerläkemedel påverkar mRNA-uttryck och kromatinorganisation i humana erytroleukemiceller. Som modell användes K562-celler från en patient i blastocystkris (2), för att utvärdera leukemicellernas svar på cancerläkemedel vinblastin och doxorubicin. Vinblastin och doxorubicin valdes på grund av deras distinkta mekanismer i cancercellen: medan doxorubicin interkaleras i DNA, hämmar topoisomeras II-aktivitet vilket orsakar celldöd, riktar vinblastin sig mot mikrotubuli för att stoppa mitotisk delning och proliferation. Uttryck av mRNA undersöktes i celler vid 0-timmar, 6-timmar och 24-timmar drogbehandling, samt efter en veckas återhämtning från 24-timmars drogbehandling. Kromatintillgänglighet med ATAC-seq undersöktes i K562-celler vid 0- timmar, 1-timmar, 6-timmar, 24-timmar och 24-timmar + en veckas återhämtning. Därefter utfördes DNA (ATAC-seq) och RNA (mRNA-seq) extraktion och biblioteksberedning på tre biologiska replikat, och öppna DNA-regioner samt mRNA expression undersöktes via sekvensering. Resultaten visade en stark korrelation mellan de biologiska replikaten, vilket indikerar att resultaten var upprepbara. Differentiellt uttryck av mRNA vid doxorubicin- och vinblastinbehandlingar utfördes genom att jämföra mRNA-nivåerna i läkemedelsbehandlade prover med obehandlade (0-timmar). Uppreglerade och nedreglerade gener identifierades och MA-grafer genererades för att visuellt analysera de differentiellt uttryckta generna vid olika tidpunkter efter läkemedelsbehandling och en veckas återhämtning. För att hitta anrikningar av funktionella genkategorier bland de läkemedelsinducerade eller -undertryckta generna, utfördes genontologianalyser. Slutligen användes verktyget Integrative Genomics Viewer (IGV) för att visuellt utforska mRNA-nivåerna och deras differentiella uttrycksmönster under läkemedelsbehandlingar. För ATAC-seq utfördes inte detaljerad dataanalys på grund av tidsbegränsning, men genomets öppenhet undersöktes visuellt genom IGV. Sammantaget inducerade doxorubicinbehandling en långsamt men långvarig förändring av genuttrycket, vilket involverade flera olika biologiska processer. Doxorubicinbehandlade K562-celler ändrade genuttryck att stöda kemoresistens snarare än att inducera apoptos eller celldöd. Behandlingen hade en långvarig inverkan på mRNA-nivåer som sträckte över återhämtningsveckan. Den totala uttrycksförändringen i återhämtningsproverna var förknippad med återhämtning av tumörigena egenskaper och återställning av mekanismener som stöder cellernas tillväxt. Vinblastine förorsakade snabb ökning av mRNA involverade i cytoskelettet. Vid 24-timmars vinblastinbehandling upplevde tumörcellerna stress på grund av grovt elongerad struktur, och de inducerade gener som stöder tumörbildning. En ökning av totala mRNA-nivåer detekterades i vinblastinbehandlade K562-leukemiceller, vilket var särskilt tydligt under återhämtningen. Resultaten visade att cellerna som överlevde vinblastinbehandling fokuserade på att återställa sin strukturella form. Sammantaget visade resultaten att monoterapi inte fungerar effektivt mot leukemiceller eftersom K562-leukemiceller inte bara överlevde läkemedelsbehandlingarna utan också inducerade mRNA som är involverade i resistens mot läkemedelsbehandlingar. / The primary objective of this project is to investigate how commonly used cancer drugs affect mRNA expression and chromatin organization in human erythroleukemia cells. As a model, K562 cells derived from a patient in blastocyst crisis (2) were utilized, evaluating the leukemia cells’ cellular responses to cancer medicines vinblastine and doxorubicin. Vinblastine and doxorubicin were chosen due to the distinct pathways they target in the cell: while doxorubicin intercalates into DNA and inhibits topoisomerase II activity, which eventually cause cell death, vinblastine targets microtubules to stops mitotic division and excessive proliferation. Expression of mRNA was investigated in cells harvested at 0h, 6h, 24h and 24h + one week recovery. Chromatin accessibility with ATAC-seq was investigated in K562 cells harvested at 0h, 1h, 6h, 24h and 24h + one week recovery. Then DNA (ATAC-seq) and RNA (mRNA-seq) extraction and library preparation were performed on three replicates, and the genome-wide results was investigated via sequencing. The results showed a strong correlation between the biological replicates, indicating that the experimental conditions were sustained in these biological variables. Differential Expression of mRNA upon doxorubicin and vinblastine treatments was performed by comparing the mRNA levels in drug-treated samples to non-treated (0h) upregulated and down regulated genes were identified and MA plots generated to visually analyze the differentially expressed genes at different time points after drug treatment and one week recovery. To find enrichments of functional gene categories among the drug-induced or -repressed genes, gene ontology analyses were performed. Finally, the Integrative genomics viewer (IGV) tool was used to visually explore the mRNA levels and their differential expression pattern during drug treatments. For ATAC-seq, detailed data analysis was not performed due to limitation of time, and data was only visually explored through IGV. Taken together, doxorubicin treatment showed slow initial response within 6h followed by an extensive change in gene expression in 24h, involving several different biological processes. The response was more inclined towards chemoresistance rather than inducing apoptosis or cell death. There was a sustained increase in mRNA levels of doxorubicin treated leukemia cells during recovery week. The overall expression change in the recovery samples was majorly linked with not only gaining back the tumourigenic properties and restoring the mechanism which were affected by doxorubicin action but, based on changes in mRNA expression, it looks like doxorubicin treatment made the tumour cells more aggressive. The initial, 6h, response to vinblastine increases mRNAs involved in cytoskeleton. Upon 24h vinblastine treatment the tumour cells experienced stress due to shear force and structural deformity, and they induced genes supporting tumourigenesis. An increase in total mRNA levels was detected in vinblastine-treated K562 leukemia cells, which was particularly evident during recovery. The results indicated that the cells that survived vinblastine treatment focused on recovering its structural form. Overall, the results indicated that monotherapy does not effectively work against leukemia cells as K562 leukemia cells not only survived the drug treatments but also induced mRNAs involved in resistance against drug treatment.